Riskpilot← Back to searchSign inGet full accessKarin Narkos AB
ABActiveOrg 5592406556Ruddammsvägen 21Medical specialists activities · NACE 8622Est. 20201 employees
Revenue 2025
SEK 0
EBITDA margin
—
-102% vs 2024
Equity ratio
51.2%
Financial strength
Net profit 2025
SEK 65K
-88% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -19K | -102% |
| Net profit | SEK 65K | -88% |
| Total assets | SEK 540K | -65% |
| Equity | SEK 277K | -51% |
| Employees | 1 | — |
Legal name
Karin Narkos AB
Org number
5592406556
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
5 februari 2020
Share capital
SEK 25 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Läkarkonsult inom anestesi. Utföra anestesi (narkos) åt privata vårdgivare och sjukhus där patienter ska genomgå kirurgi. Är specialistläkare inom anestesi och intensivvård.
Address
Ruddammsvägen 21
Email
karinstrand81@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 947 | 1 001 | 1 643 | 1 906 | 0 |
| Staff expenses | — | — | −1 222 | −1 025 | −1 |
| EBITDA | 384 | 73 | 396 | 858 | −19 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 384 | 73 | 396 | 858 | −19 |
| Net financials | — | — | 2 | 4 | 2 |
| Profit before tax | 295 | 242 | 347 | 661 | 82 |
| Tax | −61 | −50 | −71 | −136 | −18 |
| Net profit | 234 | 192 | 276 | 525 | 65 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 989 | 688 | 1 006 | 1 542 | 540 |
| Equity | 459 | 291 | 307 | 562 | 277 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 361 | 397 | 649 | 730 | 113 |
| Total debt | 361 | 397 | 649 | 730 | 113 |
EBITDA margin
-1931800.0%
This company
15.8%
Market median
-12226682% vs market
20212025
Equity ratio
51.2%
This company
38.2%
Market median
+34% vs market
20212025
Return on equity
23.4%
This company
18.4%
Market median
+27% vs market
20212025
Net profit margin
6465900.0%
This company
8.1%
Market median
+79825826% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.95×
This company
0.62×
Market median
+53% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Deputy Board Member | 2021 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Karin Narkos AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karin Maria Bergman | Board of Directors | 0 companies |
| Inger Marianne Bjurwill | Deputy Board Member | 0 companies |
| Johan Ingemar Endrell | Deputy Board Member | 0 companies |